Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Nutrition and Food Science
  •  Molecular Biology
  •  Anesthesiology and Pain Medicine
  •  Veterinary Sciences
  •  Gastric Cancer
  •  Cancer Clinic
  •  Emergency Medicine and Critical Care
  •  Microbiology


Citation: Ann Clin Case Rep. 2020;5(1):1841.DOI: 10.25107/2474-1655.1841

Full-Dose Sofosbuvir and Daclatasvir to Treat Hepatitis C Virus Infection in a 77-Year-Old Patient with Severe Renal Insufficiency

T Aatif , R Akka , and M Sbaai

Department of Nephrology and Hemodialysis, 5th Military Hospital, Guelmim, Mohammed V University, Morocco Department of Gastroenterology, 5th Military Hospital, Morocco Laboratory of Bio safety P3, 5th Military Hospital, Morocco

*Correspondance to: T Aatif 

 PDF  Full Text Case Report | Open Access


Introduction: Direct-Acting Antiviral agents (DAAs) have revolutionized the treatment of chronic Hepatitis C Virus (HCV) with Sustained Viral Response (SVR) achievable in more than 90% of all patients with few side-effects. This treatment is required to decrease the significant morbidity and mortality impact of the disease worldwide. We report a successful full dose sofosbuvir and daclatasvir treatment of HCV Infection in a patient with severe renal insufficiency. Case Presentation: A 77-year-old male with a history of Chronic Kidney Disease (CKD) stage 4 was referred to our hospital for chronic HCV. The patient was treated by a combination of full dose sofosbuvir and daclatasvir without adverse effects or interaction between this regimen and other medications used by the patient. The patient’s HCV load was undetectable at week 4, 8, 12 and a SVR was confirmed at week 48 post-treatment consistent with eradication of infection. Conclusion: This report highlighted the effectiveness and safety of the association of sofosbuvir and daclatasvir to treat HCV in the elderly with severe CKD.


Hepatitis C virus; Direct-acting antiviral; Chronic kidney disease; Elderly

Cite the Article:

T Aatif, R Akka, M Sbaai. Full-Dose Sofosbuvir and Daclatasvir to Treat Hepatitis C Virus Infection in a 77- Year-Old Patient with Severe Renal Insufficiency. Ann Clin Case Rep. 2020; 5: 1841. ISSN: 2474-1655.

Search Our Journal

Journal Indexed In

Articles in PubMed

Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and other Naturally Occurring Compounds, Part I
 PubMed  PMC  PDF  Full Text
Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Diagnostic Value of Serum Amyloid A (SAA) in Assessing the Occurrence of Acute Phase Reaction in Athletes
 Abstract  PDF  Full Text
Misdiagnosis of an Atypical Creutzfeldt-Jakob Disease: Analysis of One Case in China and Review of the Literature
 Abstract  PDF  Full Text
View More...